Dual Constant Domain‐Fab: A novel strategy to improve half‐life and potency of a Met therapeutic antibody

The kinase receptor encoded by the Met oncogene is a sensible target for cancer therapy. The chimeric monovalent Fab fragment of the DN30 monoclonal antibody (MvDN30) has an odd mechanism of action, based on cell surface removal of Met via activation of specific plasma membrane proteases. However, t...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Mol Oncol
Prif Awduron: Cignetto, Simona, Modica, Chiara, Chiriaco, Cristina, Fontani, Lara, Milla, Paola, Michieli, Paolo, Comoglio, Paolo M., Vigna, Elisa
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2016
Pynciau:
Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5423175/
https://ncbi.nlm.nih.gov/pubmed/27103110
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2016.03.004
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg